{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:51Z","timestamp":1793505651901,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["P30CA012197"],"award-info":[{"award-number":["P30CA012197"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Appendiceal cancer is a rare disease that has proven difficult to study in prospectively. Our initial report\u00a0of this trial showed minor hematologic toxicity with both mitomycin C and oxaliplatin and similar 3-year survival. We now report an update of the first prospective randomized trial for appendiceal cancer with 10-year follow up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Patients with mucinous appendiceal neoplasms and evidence of peritoneal dissemination were enrolled in the Multicenter Randomized Trial to evaluating HIPEC for 120\u00a0min with oxaliplatin (200\u00a0mg\/M<jats:sup>2<\/jats:sup>) or mitomycin C (40\u00a0mg). Overall survival and disease-free survival were calculated at 10 years and compared between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 121 patients were included in the study. The patients were 57% female, with a mean age of 55.3 years (range 22\u201382 years). The disease was low grade in 71% and high grade in 29%. The average peritoneal cancer index (PCI) score was 18 (SD 10) in the mitomycin C group and 17.9 (SD 9.4) in the oxaliplatin group (<jats:italic>p<\/jats:italic>\u2009=\u20090.94). The 10-year survival rate was 56.2% (SE 7.2) with mitomycin C and 47.5% (SE 8.4) with oxaliplatin, <jats:italic>p<\/jats:italic>\u2009=\u20090.83. The 10-year progression-free survival rate in the mitomycin C group was 45.2% (SE 8.4) compared with 50.4% (SE 6.7) in the oxaliplatin group, <jats:italic>p<\/jats:italic>\u2009=\u20090.95. Median survival was 9.1 years after HIPEC with oxaliplatin, and median not reached for the mitomycin C group (&gt;\u20095.6\u00a0years).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Oxaliplatin and mitomycin C have similar long-term efficacy for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with appendiceal neoplasms and peritoneal dissemination. Long-term survival is experienced by most patients after cytoreduction surgery (CRS) and HIPEC for appendiceal neoplasms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-16441-z","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:48:37Z","timestamp":1731422917000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7683-9502","authenticated-orcid":false,"given":"Edward A.","family":"Levine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Cos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"4","key":"16441_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11605-014-2726-7","volume":"19","author":"S Marmor","year":"2015","unstructured":"Marmor S, Portschy PR, Tuttle TM, Virnig BA. The rise in appendiceal cancer incidence: 2000\u20132009. J Gastrointest Surg. 2015;19(4):743\u201350.","journal-title":"J Gastrointest Surg."},{"issue":"4","key":"16441_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11605-008-0774-6","volume":"13","author":"AN Trivedi","year":"2009","unstructured":"Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. J Gastrointest Surg. 2009;13(4):668\u201375.","journal-title":"J Gastrointest Surg."},{"issue":"1","key":"16441_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejso.2019.09.007","volume":"46","author":"J Siddiqui","year":"2020","unstructured":"Siddiqui J, Brown K, Zahid A, Young CJ. Current practices and barriers to referral for cytoreductive surgery and HIPEC among colorectal surgeons: a binational survey. Eur J Surg Oncol. 2020;46(1):166\u201372.","journal-title":"Eur J Surg Oncol."},{"issue":"10","key":"16441_CR4","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/jcm11102840","volume":"11","author":"MM Harper","year":"2022","unstructured":"Harper MM, Kim J, Pandalai PK. Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med. 2022;11(10):2840.","journal-title":"J Clin Med."},{"issue":"4","key":"16441_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250726","volume":"16","author":"NS Rozich","year":"2021","unstructured":"Rozich NS, Lewis SE, Chen S, et al. Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. PLoS One. 2021;16(4):e0250726.","journal-title":"PLoS One."},{"issue":"20","key":"16441_CR6","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449\u201356.","journal-title":"J Clin Oncol."},{"issue":"5","key":"16441_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","volume":"36","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456\u201362.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"16441_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","volume":"15","author":"D Baratti","year":"2008","unstructured":"Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15(2):526\u201334.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"16441_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s10434-006-9708-2","volume":"13","author":"JH Stewart","year":"2006","unstructured":"Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13(5):624\u201334.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"16441_CR10","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1007\/s00464-019-07349-x","volume":"34","author":"H Abudeeb","year":"2020","unstructured":"Abudeeb H, Selvasekar CR, O\u2019Dwyer ST, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms. Surg Endosc. 2020;34(12):5516\u201321.","journal-title":"Surg Endosc."},{"issue":"4","key":"16441_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434\u201343.","journal-title":"J Am Coll Surg."},{"issue":"8","key":"16441_CR12","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","volume":"15","author":"JH Stewart","year":"2008","unstructured":"Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15(8):2137\u201345.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"16441_CR13","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.jss.2012.01.015","volume":"179","author":"K Votanopoulos","year":"2013","unstructured":"Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133-139.","journal-title":"J Surg Res."},{"issue":"7","key":"16441_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779\u201385.","journal-title":"J Surg Oncol."},{"issue":"1","key":"16441_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","volume":"43","author":"V Leung","year":"2017","unstructured":"Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(1):144\u20139.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"16441_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jso.23546","volume":"109","author":"D Hompes","year":"2014","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109(6):527\u201332.","journal-title":"J Surg Oncol."},{"issue":"5","key":"16441_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","volume":"30","author":"RF Bradley","year":"2006","unstructured":"Bradley RF, Stewart JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30(5):551\u20139.","journal-title":"Am J Surg Pathol."},{"issue":"5","key":"16441_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jamcollsurg.2006.12.048","volume":"204","author":"EA Levine","year":"2007","unstructured":"Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943\u201353 (Discussion 953\u2013945).","journal-title":"J Am Coll Surg."},{"issue":"4","key":"16441_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","volume":"218","author":"EA Levine","year":"2014","unstructured":"Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573\u201385.","journal-title":"J Am Coll Surg."},{"key":"16441_CR20","unstructured":"Health NIo. Common Terminology Criteria for Adverse Events. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed."},{"issue":"2","key":"16441_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"key":"16441_CR22","unstructured":"Cancer AJCo. Cancer Staging Manual 7th edition. In: Springer, 3\u201314."},{"issue":"4","key":"16441_CR23","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1245\/s10434-014-4147-y","volume":"22","author":"KI Votanopoulos","year":"2015","unstructured":"Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015;22(4):1274\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"16441_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681\u20135.","journal-title":"J Clin Oncol."},{"issue":"7","key":"16441_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/DCR.0000000000001076","volume":"61","author":"O Aziz","year":"2018","unstructured":"Aziz O, Jaradat I, Chakrabarty B, et al. Predicting survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendix adenocarcinoma. Dis Colon Rectum. 2018;61(7):795\u2013802.","journal-title":"Dis Colon Rectum."},{"issue":"10 Pt A","key":"16441_CR26","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ejso.2020.04.018","volume":"46","author":"C Bakkers","year":"2020","unstructured":"Bakkers C, van Erning FN, Rovers KP, et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. Eur J Surg Oncol. 2020;46(10 Pt A):1902\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"16441_CR27","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1503\/cjs.001619","volume":"64","author":"E Benzaquen","year":"2021","unstructured":"Benzaquen E, Wang Y, Wiseman S, et al. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study. Can J Surg. 2021;64(2):E111\u20138.","journal-title":"Can J Surg."},{"key":"16441_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.suronc.2018.11.006","volume":"28","author":"D Masckauchan","year":"2019","unstructured":"Masckauchan D, Trabulsi N, Dube P, et al. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis. Surg Oncol. 2019;28:69\u201375.","journal-title":"Surg Oncol."},{"issue":"13","key":"16441_CR29","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1245\/s10434-020-08790-2","volume":"27","author":"SD Forsythe","year":"2020","unstructured":"Forsythe SD, Sasikumar S, Moaven O, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27(13):4950\u201360.","journal-title":"Ann Surg Oncol."},{"key":"16441_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae049","author":"OM Fisher","year":"2024","unstructured":"Fisher OM, Brown C, Esquivel J, et al. Hyperthermic intraperitoneal chemotherapy in colorectal cancer. BJS Open. 2024. https:\/\/doi.org\/10.1093\/bjsopen\/zrae049.","journal-title":"BJS Open"},{"issue":"13","key":"16441_CR31","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.3390\/jcm12134323","volume":"12","author":"MC Pintado","year":"2023","unstructured":"Pintado MC, Lasa Unzue I, Gomez Sanz R, et al. Hematological alterations after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Med. 2023;12(13):4323.","journal-title":"J Clin Med."},{"issue":"1","key":"16441_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1245\/s10434-021-10660-4","volume":"29","author":"CW Mangieri","year":"2022","unstructured":"Mangieri CW, Valenzuela CD, Erali RA, Votanopoulos KI, Shen P, Levine EA. Incidence, risk factors, and outcomes from conversion of low-grade to high-grade appendiceal neoplasms for patients undergoing multiple cytoreductive surgeries with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2022;29(1):205\u201311.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"16441_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdr279","volume":"23","author":"CH Lieu","year":"2012","unstructured":"Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23(3):652\u20138.","journal-title":"Ann Oncol."},{"issue":"6","key":"16441_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/jso.21679","volume":"102","author":"PH Sugarbaker","year":"2010","unstructured":"Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576\u201381.","journal-title":"J Surg Oncol."},{"issue":"7","key":"16441_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jso.23547","volume":"109","author":"AU Blackham","year":"2014","unstructured":"Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740\u20135.","journal-title":"J Surg Oncol."},{"issue":"4","key":"16441_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.soc.2012.07.014","volume":"21","author":"D Elias","year":"2012","unstructured":"Elias D, Quenet F, Goere D. Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am. 2012;21(4):611\u201323.","journal-title":"Surg Oncol Clin N Am."},{"issue":"4","key":"16441_CR37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jamcollsurg.2011.12.028","volume":"214","author":"EA Levine","year":"2012","unstructured":"Levine EA, Blazer DG III, Kim MK, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599\u2013606 (discussion 597\u2013606).","journal-title":"J Am Coll Surg."},{"issue":"4","key":"16441_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2015.12.012","volume":"222","author":"EA Levine","year":"2016","unstructured":"Levine EA, Votanopoulos KI, Qasem SA, et al. Prognostic molecular subtypes of low-grade cancer of the appendix. J Am Coll Surg. 2016;222(4):493\u2013503.","journal-title":"J Am Coll Surg."},{"issue":"4","key":"16441_CR39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/SLA.0b013e31819ec7e3","volume":"249","author":"DA Schomas","year":"2009","unstructured":"Schomas DA, Miller RC, Donohue JH, et al. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience. Ann Surg. 2009;249(4):588\u201395.","journal-title":"Ann Surg."},{"issue":"3","key":"16441_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363.","journal-title":"JAMA Surg."},{"issue":"2","key":"16441_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00003088-200443020-00005","volume":"43","author":"S van Ruth","year":"2004","unstructured":"van Ruth S, Mathot RA, Sparidans RW, Beijnen JH, Verwaal VJ, Zoetmulder FA. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43(2):131\u201343.","journal-title":"Clin Pharmacokinet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16441-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16441-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16441-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T17:04:51Z","timestamp":1735923891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16441-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["16441"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16441-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nothing to disclose. Wake Forest University Comprehensive Cancer Center Biostatistics shared resource funded via the NCI Grant Award P30CA012197 and the Orin Smith Family foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}